Bachem Vionnaz, a Center of Excellence in Pharmaceutical Manufacturing

Bachem Vionnaz SA is one of the five major production sites of the Swiss Bachem Group, a world leader in the development and manufacture of peptides and oligonucleotides. Founded in 1971, the Bachem Group operates internationally with facilities in Switzerland, the United States and the United Kingdom. The Valais site, located in the Chablais region since 1973, joined the Bachem family in 2001, contributing its unique expertise in small-molecule chemistry.

Unique expertise in fine chemistry

The Vionnaz site stands out for its advanced capabilities in several areas of pharmaceutical chemistry. The specialized GMP facility produces small organic molecules and generic active pharmaceutical ingredients (APIs), which form the essential active components of many medicines.

Bachem Vionnaz has developed particular expertise in amino acid chemistry. Amino acids are fundamental building blocks of proteins and key components of numerous pharmaceutical molecules. This technical mastery enables the site to offer innovative solutions for the synthesis of complex compounds.

Electrochemistry is another area of specialization at the Valais site. This cutting-edge technology uses electrical energy to carry out precise chemical transformations, offering significant advantages in terms of selectivity and environmental sustainability. The use of electrochemistry is part of a green chemistry approach, minimizing the use of conventional chemical reagents.

Enzymatic reactions represent a third area of excellence at Bachem Vionnaz. The use of enzymes as biological catalysts allows highly selective chemical transformations to be achieved.

A GMP site meeting international standards

The Vionnaz facility operates in accordance with Good Manufacturing Practice (GMP) guidelines, ensuring compliance with the most demanding international standards in pharmaceutical quality. These certifications guarantee that all manufactured products meet strict requirements for purity, quality and traceability as set by global health authorities.

Bachem’s strategic positioning in the peptide and small-molecule markets, combined with its ongoing investments in production capacities, provides the Valais site with a solid foundation for future growth. The long-term collaborations maintained by the Group with its pharmaceutical customers also ensure strong commercial visibility and stability.